AU2002331064B2 - Peptidomimetics of biologically active metallopeptides - Google Patents

Peptidomimetics of biologically active metallopeptides Download PDF

Info

Publication number
AU2002331064B2
AU2002331064B2 AU2002331064A AU2002331064A AU2002331064B2 AU 2002331064 B2 AU2002331064 B2 AU 2002331064B2 AU 2002331064 A AU2002331064 A AU 2002331064A AU 2002331064 A AU2002331064 A AU 2002331064A AU 2002331064 B2 AU2002331064 B2 AU 2002331064B2
Authority
AU
Australia
Prior art keywords
phe
compound
following
determined
msh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002331064A
Other languages
English (en)
Other versions
AU2002331064A1 (en
Inventor
Ramesh Rajpurohit
Shubh D Sharma
Yiqun Shi
Zhijun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of AU2002331064A1 publication Critical patent/AU2002331064A1/en
Application granted granted Critical
Publication of AU2002331064B2 publication Critical patent/AU2002331064B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
AU2002331064A 2001-08-10 2002-08-12 Peptidomimetics of biologically active metallopeptides Ceased AU2002331064B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31140401P 2001-08-10 2001-08-10
US60/311,404 2001-08-10
PCT/US2002/025574 WO2003013571A1 (en) 2001-08-10 2002-08-12 Peptidomimetics of biologically active metallopeptides

Publications (2)

Publication Number Publication Date
AU2002331064A1 AU2002331064A1 (en) 2003-06-19
AU2002331064B2 true AU2002331064B2 (en) 2007-08-23

Family

ID=23206723

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002331064A Ceased AU2002331064B2 (en) 2001-08-10 2002-08-12 Peptidomimetics of biologically active metallopeptides

Country Status (6)

Country Link
US (4) US7326707B2 (US07807678-20101005-C00185.png)
EP (1) EP1425029A4 (US07807678-20101005-C00185.png)
JP (1) JP2005504043A (US07807678-20101005-C00185.png)
AU (1) AU2002331064B2 (US07807678-20101005-C00185.png)
CA (1) CA2462200A1 (US07807678-20101005-C00185.png)
WO (1) WO2003013571A1 (US07807678-20101005-C00185.png)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
CN1939529A (zh) * 2002-01-29 2007-04-04 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
WO2005102340A1 (en) * 2003-05-30 2005-11-03 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
WO2005079574A1 (en) * 2004-01-21 2005-09-01 Palatin Technologies, Inc. Bicyclic melanocorin-specific compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
WO2006081273A1 (en) * 2005-01-26 2006-08-03 Allergan, Inc. 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
AU2006332945C1 (en) 2005-12-23 2013-02-28 Wyeth Modified lysine-mimetic compounds
AU2007253819B2 (en) 2006-05-23 2011-02-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
JP2010515729A (ja) * 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
EA017797B1 (ru) 2007-04-13 2013-03-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Бициклические диазомиметики smac, способы их получения, их применения, содержащие их фармацевтические композиции и набор, содержащий указанные композиции
US20090081197A1 (en) * 2007-06-01 2009-03-26 Palatin Technologies, Inc. Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity
US20090076029A1 (en) * 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
MX2010009486A (es) 2008-02-29 2011-02-22 Mimetica Pty Ltd Antagonistas de tipo 1,4-diazepan 2 ona 3-sustituida del receptor de melanocortina-5.
CA2727803C (en) 2008-05-13 2013-03-12 University Of Kansas Metal abstraction peptide (map) tag and associated methods
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
BR112012011787B1 (pt) * 2009-11-23 2022-03-03 Palatin Technologies, Inc Peptídeo cíclico e composição farmacêutica
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
CA2815855C (en) 2010-11-01 2016-02-02 Rfs Pharma, Llc Novel specific hcv ns3 protease inhibitors
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
MX339762B (es) * 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CN104039774A (zh) 2012-01-12 2014-09-10 Rfs制药公司 Hcv ns3蛋白酶抑制剂
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
ES2870106T3 (es) 2017-05-05 2021-10-26 Zealand Pharma As Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
CN110981936B (zh) * 2018-09-28 2021-10-12 北京京东方技术开发有限公司 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148923A (en) 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US4626549A (en) 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
IT1157365B (it) 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4711957A (en) 1979-07-13 1987-12-08 The B. F. Goodrich Company Synthesis of 2-keto-1,4-diazacycloalkanes
US4434454A (en) * 1981-02-06 1984-02-28 Day J Michael Active lighting system including light control keyboard
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
US4968684A (en) 1987-04-01 1990-11-06 Janssen Pharmaceutica N.V. Method of improving sleep
FI892468A (fi) * 1988-05-23 1989-11-24 Glaxo Group Ltd Piperazinderivat.
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5120713A (en) 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
SE9202266D0 (sv) 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
US5432691A (en) * 1992-11-18 1995-07-11 Vari-Lite, Inc. Automated truss module with deployment mechanism
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
NZ263403A (en) 1993-03-25 1996-10-28 Upjohn Co (oxa)cycloalkyl fused indole and benzofuran amines
HUT70045A (en) 1993-06-17 1995-09-28 Takeda Chemical Industries Ltd 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them
US5736539A (en) * 1993-06-18 1998-04-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5599809A (en) * 1994-09-29 1997-02-04 Merck & Co., Inc. Method for improving reproductive efficiency in farm animals
US6245764B1 (en) * 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU700693B2 (en) 1995-04-13 1999-01-14 Aventis Pharmaceuticals Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
ATE215074T1 (de) * 1995-04-26 2002-04-15 Takeda Chemical Industries Ltd Piperazinone als inhibitoren von blutplattchenaggregation
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
DE19518988A1 (de) 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
US5936089A (en) * 1995-05-29 1999-08-10 Pfizer Inc Dipeptides which promote release of growth hormone
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6087357A (en) * 1995-12-18 2000-07-11 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as tachykinin antagonists
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
GB9612276D0 (en) 1996-06-12 1996-08-14 Merck & Co Inc 4-Spiroindoline piperidines promote release of growth hormone
US5804578A (en) 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
GB9611461D0 (en) * 1996-06-01 1996-08-07 Ciba Geigy Ag New compounds
US6331285B1 (en) 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
CN1195269A (zh) 1996-06-12 1998-10-07 协和发酵工业株式会社 脂质代谢改善剂
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
AU4342097A (en) 1996-09-13 1998-04-02 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JP4024309B2 (ja) * 1996-10-22 2007-12-19 第一三共株式会社 新規な感染症治療薬
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
US5965565A (en) 1996-12-12 1999-10-12 Merck & Co., Inc. Piperidines promote release of growth hormone
KR20000057595A (ko) 1996-12-17 2000-09-25 후지야마 아키라 Ｍｍｐ 또는 ｔｎｆ의 억제제로서 피페라진 화합물
DK0949905T3 (da) * 1996-12-20 2001-10-22 Alza Corp Injicertbart depotelpræparat og fremgangsmåde til fremstilling
WO1998047514A1 (en) 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
AU730843B2 (en) 1997-05-27 2001-03-15 Direct-Haler A/S Inhaler for powdered medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US5968938A (en) 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
US6287587B2 (en) * 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6211626B1 (en) * 1997-08-26 2001-04-03 Color Kinetics, Incorporated Illumination components
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US5892038A (en) * 1997-12-08 1999-04-06 Pharmacopeia, Inc. Hydroxy-amino acid amides
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
US6613234B2 (en) * 1998-04-06 2003-09-02 Ciphergen Biosystems, Inc. Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
AU3768799A (en) 1998-04-28 1999-11-16 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
DE69918296T2 (de) 1998-04-29 2005-08-04 Ortho-Mcneil Pharmaceutical, Inc. N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
IL139090A0 (en) 1998-05-11 2001-11-25 Novo Nordisk As Compounds with growth hormone releasing properties
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
EP1085869A4 (en) * 1998-06-11 2001-10-04 Merck & Co Inc SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS
KR100907638B1 (ko) * 1998-06-30 2009-07-14 노보 노르디스크 에이/에스 성장 호르몬 방출성을 가지는 화합물
FR2780649B1 (fr) * 1998-07-06 2001-03-09 Univ Paris Vii Denis Diderot Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
WO2000005373A2 (en) 1998-07-21 2000-02-03 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
ATE297908T1 (de) 1998-08-12 2005-07-15 Pfizer Prod Inc Tace inhibitoren
AU5722499A (en) * 1998-09-17 2000-04-10 Hopital Sainte-Justine G protein-coupled receptor agonists or antagonists
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6800636B2 (en) * 1998-12-18 2004-10-05 Schering Corporation Farnesyl protein transferase inhibitors
US6372747B1 (en) * 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
US6294539B1 (en) 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
DE60045216D1 (de) * 1999-03-03 2010-12-23 Optinose As Nasales Verabreichungsgerät
US6033656A (en) 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
WO2001005401A1 (en) 1999-07-16 2001-01-25 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001013112A1 (en) * 1999-08-12 2001-02-22 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
ES2264929T3 (es) 1999-09-08 2007-02-01 Genentech, Inc. Acidos nucleicos y polipeptidos del factor 19 de crecimiento fibroblastico (fgf-19) y procedimientos de utilizacion para el tratamiento de la obesidad.
GB9921239D0 (en) 1999-09-08 1999-11-10 Plant Bioscience Ltd Plant resistance gene
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6515122B1 (en) 1999-09-24 2003-02-04 Lion Bioscience Ag Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
AU1215701A (en) 1999-10-22 2001-05-08 Merck & Co., Inc. Pharmaceuticals for treating obesity
WO2001030808A1 (en) * 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) * 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
JP2001184828A (ja) * 1999-12-21 2001-07-06 Sony Corp ライナ貼付方法及びライナ貼付装置
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE19963234A1 (de) 1999-12-27 2002-01-24 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6462046B2 (en) * 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
US6693165B2 (en) * 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
US20030195212A1 (en) 2000-01-28 2003-10-16 Torbjorn Lundstedt Novel melanocortin receptor agonists and antagonists
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US20020025892A1 (en) 2000-03-17 2002-02-28 Fit Express, Inc. Golf swing conditioner
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
CA2403631A1 (en) 2000-03-23 2001-09-27 Brenda L. Palucki Spiropiperidine derivatives as melanocortin receptor agonists
AU2001249296B2 (en) 2000-03-23 2005-03-24 Merck Sharp & Dohme Corp. Substituted piperidines as melanocortin receptor agonists
EE200200567A (et) * 2000-03-31 2004-06-15 Pfizer Products Inc. Uued piperasiini derivaadid
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
EE200200717A (et) 2000-06-27 2004-08-16 Taisho Pharmaceutical Co., Ltd. Ravimpreparaat ängistusneuroosi või depressiooni raviks ja piperasiiniderivaadid
MXPA03000063A (es) 2000-06-28 2003-09-25 Pfizer Prod Inc Ligandos para receptores de malanocortina.
US6569861B2 (en) * 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
IL154575A0 (en) 2000-08-30 2003-09-17 Hoffmann La Roche Selective cyclic peptides
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
KR100394083B1 (ko) * 2000-12-04 2003-08-06 학교법인 성신학원 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법
US6612805B2 (en) 2000-12-05 2003-09-02 Emu Unterwasserpumpen Gmbh Hydrodynamic machine
CN1496254A (zh) 2000-12-15 2004-05-12 ������ҩ�����޹�˾ 男性性功能障碍的治疗
CA2432985A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Piperazine- and piperidine-derivatives as melanocortin receptor agonists
US7015235B2 (en) 2001-02-28 2006-03-21 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60232238D1 (de) 2001-02-28 2009-06-18 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
CA2439691A1 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2004532838A (ja) 2001-03-02 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
EP1385823B1 (en) 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
CA2443724C (en) 2001-05-11 2009-11-03 Patrizia Caldirola Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
CA2447314A1 (en) * 2001-05-15 2002-11-21 Atsuro Nakazato Arginine derivatives
PL208074B1 (pl) 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
US6593362B2 (en) * 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
OA12623A (en) * 2001-06-20 2006-06-12 Pfizer Prod Inc Novel sulfonic acid derivatives.
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
CN1781920A (zh) 2001-08-28 2006-06-07 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
WO2003027239A2 (en) 2001-09-26 2003-04-03 Merck & Co., Inc. Melanin-concentrating hormone receptor antagonist binding protein
WO2003031410A1 (en) 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
KR20040047941A (ko) * 2001-10-22 2004-06-05 화이자 프로덕츠 인크. Ｃｃｒ1 수용체 길항제 활성을 갖는 피페라진 유도체
JP4436676B2 (ja) 2001-11-08 2010-03-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド メラノコルチン受容体調節剤としての新規な１，２，４−チアジアゾール誘導体
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
AU2002367087A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
KR20040083472A (ko) * 2001-12-21 2004-10-02 다이쇼 세이야꾸 가부시끼가이샤 피페라진 유도체
WO2003061660A1 (en) 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
US20030207814A1 (en) 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030195187A1 (en) 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
EP1487474A4 (en) 2002-02-25 2006-11-29 Chiron Corp INTRANASAL ADMINISTRATION OF MC4-R AGONISTS
EP1503761A1 (en) 2002-05-10 2005-02-09 Neurocrine Biosciences, Inc. Substituted piperazines as melanocortin receptor ligands
US7160886B2 (en) 2003-03-03 2007-01-09 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
US7834017B2 (en) * 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US20090076029A1 (en) * 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity

Also Published As

Publication number Publication date
JP2005504043A (ja) 2005-02-10
US7326707B2 (en) 2008-02-05
US7601753B2 (en) 2009-10-13
WO2003013571A1 (en) 2003-02-20
US20070155670A1 (en) 2007-07-05
US7807678B2 (en) 2010-10-05
CA2462200A1 (en) 2003-02-20
US20040167201A1 (en) 2004-08-26
EP1425029A4 (en) 2006-06-07
EP1425029A1 (en) 2004-06-09
US20040152134A1 (en) 2004-08-05
US20040171520A1 (en) 2004-09-02
US7189755B2 (en) 2007-03-13

Similar Documents

Publication Publication Date Title
AU2002331064B2 (en) Peptidomimetics of biologically active metallopeptides
AU2002331064A1 (en) Peptidomimetics of biologically active metallopeptides
CN100384819C (zh) 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
AU2002322466B2 (en) Linear and cyclic melanocortin receptor-specific peptides
Williams et al. 1-(((7, 7-Dimethyl-2 (S)-(2 (S)-amino-4-(methylsulfonyl) butyramido) bicyclo [2.2. 1] heptan-1 (S)-yl) methyl) sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor
US7964601B2 (en) Melanocortin receptor-specific compounds
Sun et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics
Cai et al. Biological and conformational study of β‐substituted prolines in MT‐II template: steric effects leading to human MC5 receptor selectivity
US7354923B2 (en) Piperazine melanocortin-specific compounds
Creighton et al. Design, synthesis, and conformational analysis of eight-membered cyclic peptidomimetics prepared using ring closing metathesis
US7385025B2 (en) Metallopeptide compounds
Bourguet et al. Benzophenone semicarbazone protection strategy for synthesis of aza‐glycine containing aza‐peptides
Lee et al. Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at μ and δ opioid receptors
Mollica et al. Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers
Zask et al. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents
Hiebl et al. Large‐scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling
Shreder et al. Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue (MABE): a new route to cyclic peptides and peptidomimetics
Tian et al. Discovery of orally bioavailable 1, 3, 4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents
US7049398B1 (en) Melanocortin metallopeptide constructs, combinatorial libraries and applications
Chang et al. The discovery of small molecule carbamates as potent dual α4β1/α4β7 integrin antagonists
US6495358B1 (en) Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
Fry et al. Utilizing peptide structures as keys for unlocking challenging targets
WO2005102340A1 (en) Piperazine melanocortin-specific compounds
Biitseva et al. 1H‐Isoindole‐Based Potential Peptidomimetics
ZA200509683B (en) Melanocortin receptor-specific compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired